RecruitingPhase 1NCT07560943
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
Studying Polyarteritis nodosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- West China Hospital
- Intervention
- PAN-NeoVax (25 μg)(biological)
- Enrollment
- 9 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2026 – 2027
Study locations (2)
- West China Hospital, Chengdu, Sichuan, China
- The West China Hospital, Chengdu, Sichuan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07560943 on ClinicalTrials.govOther trials for Polyarteritis nodosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07584044A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor TherapyTianjin Medical University Cancer Institute and Hospital
- ACTIVE NOT RECRUITINGNCT07554157Development of a Pan-Cancer Screening Model Based on Blood BiomarkersZhejiang Cancer Hospital